Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976971 | 0.90 | HDAC1 (0.53) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL19976980 | 0.85 | NPC1 (0.66) | HTTKMT2ARAB9AMEN1TSHR | |
| SCHEMBL19976916 | 0.84 | KMT2A (0.51) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL19977035 | 0.84 | KMT2A (0.61) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL19976899 | 0.84 | KMT2A (0.49) | SMN1; SMN2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL19977046 | 0.83 | KMT2A (0.50) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL19977006 | 0.82 | APLNR (0.54) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL16999313 | 0.81 | HTT (0.55) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL18261154 | 0.81 | HTT (0.55) | SMN1; SMN2HTTKMT2ARAB9AMEN1 | |
| SCHEMBL12780373 | 0.81 | KMT2A (0.66) | SMN1; SMN2HTTKMT2ARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198279-A1 | ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-07-01 | — | — | US | disclosed |
| US-9919998-B2 | Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198279-A1 | ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS | POLM, POLR2E, POLR2H | SMN1; SMN2 4390/4885HTT 4460/4885KMT2A 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.